Please review the QC test results indicated by 
icon below as well as clone information before placing your order.
提供案内 (日本国内) 
[open/close]
Please review the QC test results indicated by icon below as well as clone information before placing your order.
icon below as well as clone information before placing your order.
pCMFlag_hsCREB1, transcript variant B (#RDB07505)
Expression vector of human CREB1.
| Alternative name | SET-0328_1-1 |
|---|---|
| Clone info. | Expression vector of human CREB1. Expression has not yet been confirmed. |
| Comment | PCR cloning, forward primer: ATGACCATGGAATCTGGAGCCGA; reverse primer: AATTAATCTGATTTGTGGCAGTAAA. |
| Vector backbone | pCMV_S-FLAG (RDB05956) (Plasmid) |
| Selectable markers | Amp^r (E. coli), Neo^r (mammalian cell) |
| Growth conditions | 37C, LB+Amp |
| Gene/insert name | Human CREB1,transcript variant B cDNA |
| Depositor|Developer | DNA Bank, | |
Distribution information
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
| Ordering forms | Order form [Credit Card Payment  ] [Bank Transfer Payment] [Example of order form ]MTA, for use for not-for-profit academic purpose [Word ] [Example of MTA ]MTA, for use for for-profit purpose [Word ]Please visit Information of Request for Distribution.[link] |
|---|---|
| Terms and conditions for distribution | The RECIPIENT agrees to describe RIKEN BRC as the source of the MATERIAL in any publication. Additional terms and conditions: Regrding pRc/CMV: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
[open/close]| 必要書類 | 提供依頼書 [依頼書の記入例 ]提供同意書 (MTA, 非営利学術目的用)[Word ] [MTAの記入例 ]提供同意書 (MTA, 営利目的用)[Word ]手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
|---|---|
| MTAに書く使用条件 | 発表に際し、理研BRCから入手したことを明記すること。 付加的使用条件： pRc/CMVについて: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
| Catalog # | Resource name | Shipping form | Fee |
|---|---|---|---|
| RDB07505 | pCMFlag_hsCREB1, transcript variant B | DNA solution |
JPY 9,460 (not-for-profit academic purpose) JPY 18,920 (for-profit-research purpose) plus cost of shipping containers, dry ice (if required) and shipping charge |
icon below as well as clone information before placing your order.How to cite this biological resource
Materials & Methods section:
| The pCMFlag_hsCREB1, transcript variant B was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07505). |
Reference section:
Further references such as user reports and related articles (go to bottom)
QC test results
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
| Test sheet | RDB07505_A4Eep1-2.pdf |
|---|
Nucleotide sequence of a portion of this resource (if available).
|
Primer: CMV_Forward (Pr0016) Region: CMV pro,T7 pro,FLAG, insert 5' Sequence file: RDB07505_A4Eec.seq
|
|---|
|
>07505_07505_A4Ee_CMV-Foward_C02_08.ab1 1 NNNNNNNNNN NNNNNNNNNN NNNNNGCNNA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT 61 ATATAAGCAG AGCTCTCTGG CTAACTAGAG AACCCACTGC TTACTGGCTT ATCGAAATTA 121 ATACGACTCA CTATAGGGAG ACCCAAGCTG AATTCACCAT GGACTACAAG GACGATGACG 181 ATAAGGCGGC CATGACCATG GAATCTGGAG CCGAGAACCA GCAGAGTGGA GATGCAGCTG 241 TAACAGAAGC TGAAAACCAA CAAATGACAG TTCAAGCCCA GCCACAGATT GCCACATTAG 301 CCCAGGTATC TATGCCAGCA GCTCATGCAA CATCATCTGC TCCCACCGTA ACTCTAGTAC 361 AGCTGCCCAA TGGGCAGACA GTTCAAGTCC ATGGAGTCAT TCAGGCGGCC CAGCCATCAG 421 TTATTCAGTC TCCACAAGTC CAAACAGTTC AGTCTTCCTG TAAGGACTTA AAAAGACTTT 481 TCTCCGGAAC ACAGATTTCA ACTATTGCAG AAAGTGAAGA TTCACAGGAG TCAGTGGATA 541 GTGTAACTGA TTCCCAAAAG CGAAGGGAAA TTCTTTCAAG GAGGCCTTCC TACAGGAAAA 601 TTTTGAATGA CTTATCTTCT GATGCACCAG GAGTGCCAAG GATTGAAGAA GAGAAGTCTG 661 AAGAGGAGAC TTCAGCACCT GCCATCACCA CTGTAACGGT GCCNACTCCA ATTTACCAAA 721 CTAGCAGTGG ACAGTATATT GCCATTACCC AGGGANGAGC AATACAGCTG GCTAACAATG 781 GTACCGATGG GGTACAGGGC CTGCAAACAT TAACCATGAC CAATGCAGCA GCCACTCAGC 841 CGGGTACTAC CATTCTACAG TATGCACAGA CCACTGATGG ACAGCAGATC TNANTGCCNA 901 NCNACCAAGT TGTTGTTCNA GCTGCCTCTG GAGACGTACA AACATACNNG ANTCGCACAG 961 CACCNACTAN CACTATTGCC NNNNGNNTNG NNNTNGNNTN CNCCCNNNCN NNNNCNNANN 1021 NNNNCNNNNN NNANNNNNNN NNN // |
|
Primer: bGH_rev3 (Pr0885) Region: bGH pA,SP6 pro,insert 3' Sequence file: RDB07505_A4Eed.seq
|
|
>07505_07505_B3KhS_bGH_rev3_F01_06_ABI08.ab1 1 NNNNNNNNNN NNNNGGNNGN NGGGCNNACA ACAGATGGCT GGCAACTAGA AGGCACAGTC 61 GAGGCTGATC AGCGAGCTCT AGCATTTAGG TGACACTATA GAATAGGGCC CTCTAGATGC 121 ATGCTCGAGC GGCCAATTAA TCTGATTTGT GGCAGTAAAG GTCCTTAAGT GCTTTTAGCT 181 CCTCAATCAA TGTCTTGTTT TGATTTTCAA GCACTGCCAC TCTGTTTTCT AAACATTTCA 241 CATATTCTTT CTTCTTTCTA CGACACTCTC GAGCTGCTTC CCTGTTCTTC ATTAGACGGA 301 CCTCTCTCTT TCGTGCTGCT TCTTCAGCAG GCTGTGTAGG AAGTGCTGGG GAGGATGCCA 361 TAACAACTCC AGGGGCAATA GTGCTAGTGG GTGCTGTGCG AATCTGGTAT GTTTGTACGT 421 CTCCAGAGGC AGCTTGAACA ACAACTTGGT TGCTGGGCAC TAAGATCTGC TGTCCATCAG 481 TGGTCTGTGC ATACTGTAGA ATGGTAGTAC CCGGCTGAGT GGCTGCTGCA TTGGTCATGG 541 TTAATGTTTG CAGGCCCTGT ACCCCATCGG TACCATTGTT AGCCAGCTGT ATTGCTCCTC 601 CCTGGGTAAT GGCAATATAC TGTCCACTGC TAGTTTGGTA AATTGGAGTT GGCACCGTTA 661 CNGTGNTGAN GNCANGTGCT GANNTCTCCT CTTCNNANTT CTCTTCNTCN NNNCNNNNGN 721 ANTCCNNNNN NNNNN // |
|
Primer: SV40pro_ori_F (Pr0731) Region: SV40 pro_ori,NeoR Sequence file: RDB07505_A4Eee.seq
|
|
>07505_07505_B3KhS_SV40pro_ori_F_G01_07_ABI08.ab1 1 NNNNNNNNNN NNNNNNNNNN GCNGCCTCNG CCTCTNNNCT ATTCNNGAAG TAGTGAGGAG 61 GCTTTTTTGG AGGCCTANGC TTTTGCAAAA AGCTCCCGGG AGCTTGGATA TCCATTTTCG 121 GATCTGATCA AGAGACAGGA TGAGGATCGT TTCGCATGAT TGAACAAGAT GGATTGCACG 181 CAGGTTCTCC GGCCGCTTGG GTGGAGAGGC TATTCGGCTA TGACTGGGCA CAACAGACAA 241 TCGGCTGCTC TGATGCCGCC GTGTTCCGGC TGTCAGCGCA GGGGCGCCCG GTTCTTTTTG 301 TCAAGACCGA CCTGTCCGGT GCCCTGAATG AACTGCAGGA CGAGGCAGCG CGGCTATCGT 361 GGCTGGCCAC GACGGGCGTT CCTTGCGCAG CTGTGCTCGA CGTTGTCACT GAAGCGGGAA 421 GGGACTGGCT GCTATTGGGC GAAGTGCCGG GGCAGGATCT CCTGTCATCT CACCTTGCTC 481 CTGCCGAGAA AGTATCCATC ATGGCTGATG CAATGCGGCG GCTGCATACG CTTGATCCGG 541 CTACCTGCCC ATTCGACCAC CAAGCGAAAC ATCGCATCGA GCGAGCACGT ACTCGGATGG 601 AAGCCGGTCT TGTCGATCAN GANGATCTGG ACGAANAGCA TCNNGGGCTC GCGCCNGCCG 661 AACTGTTCGN CAGGCTNNAN NNGCGCATGC CCNACGGCGA NGNNCTCNTC NNGACCCANG 721 NNNNNGCNNG CTNNNNNNAN NNNNNNNNN // |
Please visit 
Sequencing and PCR primers for primer information.
References
Original, user report and related articles
Resource search
Link
Other resources in our bankExternal Database
Human CREB1,transcript variant B
Reference sequence
Tips
Featured content
